These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 36109762)
1. Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes. Xia J; Zhang S; Zhang R; Wang A; Zhu Y; Dong M; Ma S; Hong C; Liu S; Wang D; Wang J J Nanobiotechnology; 2022 Sep; 20(1):414. PubMed ID: 36109762 [TBL] [Abstract][Full Text] [Related]
2. Versatile ginsenoside Rg3 liposomes inhibit tumor metastasis by capturing circulating tumor cells and destroying metastatic niches. Xia J; Ma S; Zhu X; Chen C; Zhang R; Cao Z; Chen X; Zhang L; Zhu Y; Zhang S; Li S; Gu G; Wei X; Yu K; Wang J Sci Adv; 2022 Feb; 8(6):eabj1262. PubMed ID: 35148178 [TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells. Zhu Y; Wang A; Zhang S; Kim J; Xia J; Zhang F; Wang D; Wang Q; Wang J J Adv Res; 2023 Jul; 49():159-173. PubMed ID: 36167294 [TBL] [Abstract][Full Text] [Related]
4. Ginsenoside Rg3 liposomes regulate tumor microenvironment for the treatment of triple negative breast cancer. Miao L; Ma H; Dong T; Zhao C; Gao T; Wu T; Xu H; Zhang J Drug Dev Ind Pharm; 2023 Jan; 49(1):139-148. PubMed ID: 36881020 [TBL] [Abstract][Full Text] [Related]
5. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment. Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040 [TBL] [Abstract][Full Text] [Related]
6. Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy. Zhu Y; Liang J; Gao C; Wang A; Xia J; Hong C; Zhong Z; Zuo Z; Kim J; Ren H; Li S; Wang Q; Zhang F; Wang J J Control Release; 2021 Feb; 330():641-657. PubMed ID: 33359582 [TBL] [Abstract][Full Text] [Related]
7. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer. Yuan Z; Jiang H; Zhu X; Liu X; Li J Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544 [TBL] [Abstract][Full Text] [Related]
8. Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer. Luo X; Wang H; Ji D Aging (Albany NY); 2021 Jun; 13(13):17177-17189. PubMed ID: 34111025 [TBL] [Abstract][Full Text] [Related]
9. In silico ADMET profiling of Docetaxel and development of camel milk derived liposomes nanocarriers for sustained release of Docetaxel in triple negative breast cancer. Kousar K; Shafiq S; Sherazi ST; Iqbal F; Shareef U; Kakar S; Ahmad T Sci Rep; 2024 Jan; 14(1):912. PubMed ID: 38195628 [TBL] [Abstract][Full Text] [Related]
10. Efficient Sequential Co-Delivery Nanosystem for Inhibition of Tumor and Tumor-Associated Fibroblast-Induced Resistance and Metastasis. Li C; Wang Z; Zhang Y; Zhu Y; Xu M; Lei H; Zhang D Int J Nanomedicine; 2024; 19():1749-1766. PubMed ID: 38414527 [TBL] [Abstract][Full Text] [Related]
11. Multifunctional Biomimetic Liposomes with Improved Tumor-Targeting for TNBC Treatment by Combination of Chemotherapy, Antiangiogenesis and Immunotherapy. Lan J; Chen L; Li Z; Liu L; Zeng R; He Y; Shen Y; Zhang T; Ding Y Adv Healthc Mater; 2024 Oct; 13(26):e2400046. PubMed ID: 38767575 [TBL] [Abstract][Full Text] [Related]
12. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy. Fan Y; Wang Q; Lin G; Shi Y; Gu Z; Ding T Acta Biomater; 2017 Oct; 62():257-272. PubMed ID: 28859899 [TBL] [Abstract][Full Text] [Related]
13. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Takai K; Le A; Weaver VM; Werb Z Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881 [TBL] [Abstract][Full Text] [Related]
14. Sialic acid-decorated liposomes enhance the anti-cancer efficacy of docetaxel in tumor-associated macrophages. Tran NP; Tran P; Yoo SY; Tangchang W; Lee S; Lee JY; Son HY; Park JS Biomater Adv; 2023 Nov; 154():213606. PubMed ID: 37678087 [TBL] [Abstract][Full Text] [Related]
15. Biomimetic "nano-spears" for CAFs-targeting: splintered three "shields" with enhanced cisplatin anti-TNBC efficiency. Wu Y; Chen R; Ni S; Hu K J Control Release; 2024 Jun; 370():556-569. PubMed ID: 38697316 [TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy. Jain S; Deore SV; Ghadi R; Chaudhari D; Kuche K; Katiyar SS Mater Sci Eng C Mater Biol Appl; 2021 Feb; 121():111832. PubMed ID: 33579470 [TBL] [Abstract][Full Text] [Related]
17. [Ginsenoside Rg_3 based liposomes target delivery of dihydroartemisinin and paclitaxel for treatment of triple-negative breast cancer]. Liu H; Liu Y; Li N; Zhang GQ; Wang M Zhongguo Zhong Yao Za Zhi; 2023 Jul; 48(13):3472-3484. PubMed ID: 37474984 [TBL] [Abstract][Full Text] [Related]
18. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. Doddapaneni R; Patel K; Chowdhury N; Singh M Exp Cell Res; 2016 Aug; 346(1):65-73. PubMed ID: 27177833 [TBL] [Abstract][Full Text] [Related]
19. Docetaxel in combination with metformin enhances antitumour efficacy in metastatic breast carcinoma models: a promising cancer targeting based on PEGylated liposomes. Vakili-Ghartavol R; Mehrabian A; Mirzavi F; Rezayat SM; Mashreghi M; Farhoudi L; Kharrazi S; Sadri K; Jaafari MR J Pharm Pharmacol; 2022 Sep; 74(9):1307-1319. PubMed ID: 35833585 [TBL] [Abstract][Full Text] [Related]
20. Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression. Liu B; Yang Q; Cheng Y; Liu M; Ji Q; Zhang B; Yang Z; Zhou S; Liu D Acta Biomater; 2023 Aug; 166():640-654. PubMed ID: 37236576 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]